We are live on ! Find out more
ALGS icon

Aligos Therapeutics
ALGS

35 hedge funds and large institutions have $19.2M invested in Aligos Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.05% less ownership

Funds ownership: 2.6% → 2.55% (-0.05%)

15% less funds holding

Funds holding: 41 → 35 (-6)

25% less capital invested

Capital invested by funds: $25.5M → $19.2M (-$6.3M)

67% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 9

86% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 7

Holders
35
Holders Change
-6
Holders Change %
-14.63%
% of All Funds
0.56%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
1
Increased
3
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NM
Newtyn Management
New York
+$17.7K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$14.1K
3
Creative Planning
Creative Planning
Kansas
+$8.91K
4
UBS Group
UBS Group
Switzerland
+$4.7K

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$174K
2
Renaissance Technologies
Renaissance Technologies
New York
-$96.8K
3
Millennium Management
Millennium Management
New York
-$74.5K
4
Deutsche Bank
Deutsche Bank
Germany
-$69.2K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$50.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Carson Wealth (CWM LLC)
26
Carson Wealth (CWM LLC)
Nebraska
$13K – – –
Creative Planning
27
Creative Planning
Kansas
$7.51K +$8.91K +402 New
UBS Group
28
UBS Group
Switzerland
$4.06K +$4.7K +212 +4,240%
Morgan Stanley
29
Morgan Stanley
New York
$1.49K -$886 -40 -33%
Fidelity Investments
30
Fidelity Investments
Massachusetts
$896 – – –
JP Morgan Chase
31
JP Morgan Chase
New York
$506 – – –
Federated Hermes
32
Federated Hermes
Pennsylvania
$488 -$864 -39 -60%
Wells Fargo
33
Wells Fargo
California
$146 – – –
EWP
34
Elevation Wealth Partners
California
$75 – – –
NFSG
35
Newbridge Financial Services Group
Florida
$28 – – –
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$1 – – –
Deutsche Bank
37
Deutsche Bank
Germany
– -$69.2K -2,852 Closed
Two Sigma Advisers
38
Two Sigma Advisers
New York
– -$50.9K -2,096 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$27.1K -1,114 Closed
VF
40
Virtu Financial
New York
– -$18K -734 Closed
HF
41
HRT Financial
New York
– -$9K -404 Closed
Osaic Holdings
42
Osaic Holdings
Arizona
– -$7.77K -320 Closed
Simplex Trading
43
Simplex Trading
Illinois
– -$1K -48 Closed
1
2

ALGS Hedge Fund Activity: Q3 2023 in Review

35 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q3 2023, worth a combined $19.2M — down 25% from $25.5M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ALGS and 1 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 3 added.

The largest buyer was Newtyn Management, adding an estimated $17.7K. The largest seller was Royal Bank of Canada, cutting an estimated $174K.

  • 35 institutional investors held Aligos Therapeutics (ALGS) as of Q3 2023, down from 41 in Q2 2023.
  • Funds reported $19.2M of Aligos Therapeutics stock for Q3 2023, down 25% quarter-over-quarter.
  • 1 fund opened new Aligos Therapeutics positions in Q3 2023 and 7 closed out, a net change of -6 holders.
  • The largest Aligos Therapeutics buyer in Q3 2023 was Newtyn Management, an estimated $17.7K added.
  • The largest Aligos Therapeutics seller in Q3 2023 was Royal Bank of Canada, an estimated $174K sold.

Based on aggregated 13F filings for Q3 2023.